Cargando…

COT-19 TREATMENT EXPERIENCE OF AND TIPS FOR ADMINISTRATING NOVO TTF

BACKGROUNDS: Current standard of care for glioblastoma, consists of postoperative temozolomide (TMZ) concomitant with radiotherapy, followed by adjuvant TMZ monotherapy. Recently, an international phase 3 trial (EF-14) demonstrated that addition of tumor-treating fields (TTF) to adjuvant TMZ after c...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimada, Daisuke, Kobayashi, Keiichi, Saito, Kuniaki, Matsumoto, Yoshie, Shiokawa, Yoshiaki, Nagane, Motoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213441/
http://dx.doi.org/10.1093/noajnl/vdz039.199
_version_ 1783531804432531456
author Shimada, Daisuke
Kobayashi, Keiichi
Saito, Kuniaki
Matsumoto, Yoshie
Shiokawa, Yoshiaki
Nagane, Motoo
author_facet Shimada, Daisuke
Kobayashi, Keiichi
Saito, Kuniaki
Matsumoto, Yoshie
Shiokawa, Yoshiaki
Nagane, Motoo
author_sort Shimada, Daisuke
collection PubMed
description BACKGROUNDS: Current standard of care for glioblastoma, consists of postoperative temozolomide (TMZ) concomitant with radiotherapy, followed by adjuvant TMZ monotherapy. Recently, an international phase 3 trial (EF-14) demonstrated that addition of tumor-treating fields (TTF) to adjuvant TMZ after completion of chemoradiotherapy extended median progression-free survival and overall survival by 2.7 months and 4.8 months, respectively, compared with TMZ alone in patients with newly diagnosed glioblastoma. TTF is now considered as a part of its initial treatment in the guideline in Japan (recommendation grade B). However,distinct from anticancer drugs,little is known or experienced using TTF as a therapeutic device so far, especially in management and handling. METHODS: First six patients with newly diagnosed glioblastoma who underwent TTF were analyzed with special interest in medical and social supports to execute TTF at home. RESULTS: TTF was first introduced in our institution in May 2016, but no patients were treated because of no coverage by medical insurance until December 2017. We further needed to wait to initiate TTF treatment until January 2019 when the contract to use TTF systems was finally made between the company and institution. Since then six patients were registered in five months. For its introduction to clinical practice,it is essential to establish new in-house environment with medical professions division in the facility including documentations of calculating instruction fees and usage guidance for home care application of TTF. It is also important to initiate providing information of TTF such as timing of visit by specific practitioners and potential medical and psychologic burdens to patients and their families during and after chemoradiotherapy to better understand this new modality leading to the consent acquisition. CONCLUSIONS: Introducing TTF into clinical practice should accompany improvement of management in not only medical equipment and documentations but also patient care in hospital and home.
format Online
Article
Text
id pubmed-7213441
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72134412020-07-07 COT-19 TREATMENT EXPERIENCE OF AND TIPS FOR ADMINISTRATING NOVO TTF Shimada, Daisuke Kobayashi, Keiichi Saito, Kuniaki Matsumoto, Yoshie Shiokawa, Yoshiaki Nagane, Motoo Neurooncol Adv Abstracts BACKGROUNDS: Current standard of care for glioblastoma, consists of postoperative temozolomide (TMZ) concomitant with radiotherapy, followed by adjuvant TMZ monotherapy. Recently, an international phase 3 trial (EF-14) demonstrated that addition of tumor-treating fields (TTF) to adjuvant TMZ after completion of chemoradiotherapy extended median progression-free survival and overall survival by 2.7 months and 4.8 months, respectively, compared with TMZ alone in patients with newly diagnosed glioblastoma. TTF is now considered as a part of its initial treatment in the guideline in Japan (recommendation grade B). However,distinct from anticancer drugs,little is known or experienced using TTF as a therapeutic device so far, especially in management and handling. METHODS: First six patients with newly diagnosed glioblastoma who underwent TTF were analyzed with special interest in medical and social supports to execute TTF at home. RESULTS: TTF was first introduced in our institution in May 2016, but no patients were treated because of no coverage by medical insurance until December 2017. We further needed to wait to initiate TTF treatment until January 2019 when the contract to use TTF systems was finally made between the company and institution. Since then six patients were registered in five months. For its introduction to clinical practice,it is essential to establish new in-house environment with medical professions division in the facility including documentations of calculating instruction fees and usage guidance for home care application of TTF. It is also important to initiate providing information of TTF such as timing of visit by specific practitioners and potential medical and psychologic burdens to patients and their families during and after chemoradiotherapy to better understand this new modality leading to the consent acquisition. CONCLUSIONS: Introducing TTF into clinical practice should accompany improvement of management in not only medical equipment and documentations but also patient care in hospital and home. Oxford University Press 2019-12-16 /pmc/articles/PMC7213441/ http://dx.doi.org/10.1093/noajnl/vdz039.199 Text en © The Author(s) 2019. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Shimada, Daisuke
Kobayashi, Keiichi
Saito, Kuniaki
Matsumoto, Yoshie
Shiokawa, Yoshiaki
Nagane, Motoo
COT-19 TREATMENT EXPERIENCE OF AND TIPS FOR ADMINISTRATING NOVO TTF
title COT-19 TREATMENT EXPERIENCE OF AND TIPS FOR ADMINISTRATING NOVO TTF
title_full COT-19 TREATMENT EXPERIENCE OF AND TIPS FOR ADMINISTRATING NOVO TTF
title_fullStr COT-19 TREATMENT EXPERIENCE OF AND TIPS FOR ADMINISTRATING NOVO TTF
title_full_unstemmed COT-19 TREATMENT EXPERIENCE OF AND TIPS FOR ADMINISTRATING NOVO TTF
title_short COT-19 TREATMENT EXPERIENCE OF AND TIPS FOR ADMINISTRATING NOVO TTF
title_sort cot-19 treatment experience of and tips for administrating novo ttf
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213441/
http://dx.doi.org/10.1093/noajnl/vdz039.199
work_keys_str_mv AT shimadadaisuke cot19treatmentexperienceofandtipsforadministratingnovottf
AT kobayashikeiichi cot19treatmentexperienceofandtipsforadministratingnovottf
AT saitokuniaki cot19treatmentexperienceofandtipsforadministratingnovottf
AT matsumotoyoshie cot19treatmentexperienceofandtipsforadministratingnovottf
AT shiokawayoshiaki cot19treatmentexperienceofandtipsforadministratingnovottf
AT naganemotoo cot19treatmentexperienceofandtipsforadministratingnovottf